354 related articles for article (PubMed ID: 36389768)
21. Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
Delaye M; Rousseau A; Mailly-Giacchetti L; Assoun S; Sokol H; Neuzillet C
Pharmacol Ther; 2023 Jul; 247():108442. PubMed ID: 37210004
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
Dougan M
Immunol Rev; 2023 Sep; 318(1):11-21. PubMed ID: 37455375
[TBL] [Abstract][Full Text] [Related]
23. Complex interactions between the microbiome and cancer immune therapy.
Schwartz DJ; Rebeck ON; Dantas G
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
[TBL] [Abstract][Full Text] [Related]
24. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
25. Gut microbiota and immunotherapy of renal cell carcinoma.
Bibbò S; Porcari S; Del Vecchio LE; Severino A; Mullish BH; Ianiro G; Gasbarrini A; Cammarota G
Hum Vaccin Immunother; 2023 Dec; 19(3):2268982. PubMed ID: 37955340
[TBL] [Abstract][Full Text] [Related]
26. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors.
Zhang Y; Cheng S; Zou H; Han Z; Xie T; Zhang B; Dai D; Yin X; Liang Y; Kou Y; Tan Y; Shen L; Peng Z
Front Cell Infect Microbiol; 2023; 13():1099063. PubMed ID: 37051296
[TBL] [Abstract][Full Text] [Related]
27. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau HCH; Sung JJ; Yu J
Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
[TBL] [Abstract][Full Text] [Related]
29. Gut microbiome and checkpoint inhibitor colitis.
Sehgal K; Khanna S
Intest Res; 2021 Oct; 19(4):360-364. PubMed ID: 33249800
[TBL] [Abstract][Full Text] [Related]
30. Check this out: treatment paradigms in immune-checkpoint inhibitor colitis.
Kiparizoska S; Murphy ME; Mattar MC
Curr Opin Gastroenterol; 2023 Jan; 39(1):43-49. PubMed ID: 36504035
[TBL] [Abstract][Full Text] [Related]
31. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
Abu-Sbeih H; Ali FS; Wang Y
Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
[TBL] [Abstract][Full Text] [Related]
32. Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis.
Abu-Sbeih H; Wang Y
Dig Dis Sci; 2020 Mar; 65(3):797-799. PubMed ID: 32040664
[TBL] [Abstract][Full Text] [Related]
33. Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review.
Hwang SW; Kim MK; Kweon MN
Intest Res; 2023 Oct; 21(4):433-442. PubMed ID: 37640378
[TBL] [Abstract][Full Text] [Related]
34. Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors.
Luo B; Zhang Y; Zhang C; Liu X; Shi C
Cancer Lett; 2021 Jul; 509():53-62. PubMed ID: 33845122
[TBL] [Abstract][Full Text] [Related]
35. Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.
Liu W; Ma F; Sun B; Liu Y; Tang H; Luo J; Chen H; Luo Z
Front Immunol; 2021; 12():756872. PubMed ID: 34975845
[TBL] [Abstract][Full Text] [Related]
36. Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events.
Liu X; Tang H; Zhou Q; Zeng Y; Lu B; Chen D; Li Y; Qian J; Chen M; Zhao J; Xu Y; Wang M; Tan B
Front Immunol; 2023; 14():1109281. PubMed ID: 36891304
[TBL] [Abstract][Full Text] [Related]
37. Improving ICI outcomes with a little help from my microbial friends.
Rebeck ON; Dantas G; Schwartz DJ
Cell Host Microbe; 2021 Feb; 29(2):155-157. PubMed ID: 33571442
[TBL] [Abstract][Full Text] [Related]
38. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
39. Fecal microbiota transplantation ameliorates experimental colitis
Wen X; Wang HG; Zhang MN; Zhang MH; Wang H; Yang XZ
World J Gastroenterol; 2021 Jun; 27(21):2834-2849. PubMed ID: 34135557
[TBL] [Abstract][Full Text] [Related]
40. Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light.
Zhang J; Wu K; Shi C; Li G
Curr Treat Options Oncol; 2022 Dec; 23(12):1777-1792. PubMed ID: 36279081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
